Heterotetrameric forms of human phenylalanine hydroxylase: Co-expression of wild-type and mutant forms in a bicistronic system

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1812, Issue 5, 2011, Pages 602-612

  Leandro, João ^a,b   Leandro, Paula ^b   Flatmark, Torgeir ^a  

^a UNIVERSITY OF BERGEN   (Norway)

^b UNIVERSITY OF LISBON   (Portugal)

Author keywords

Bicistronic system; Heteroallelic protein; Human phenylalanine hydroxylase; Hybrid protein; Interallelic complementation; Phenylketonuria

Indexed keywords

HETERODIMER; HOMODIMER; PHENYLALANINE 4 MONOOXYGENASE; TRYPSIN;

ARTICLE; BICISTRONIC EXPRESSION SYSTEM; CATALYSIS; CONFORMATIONAL TRANSITION; ENZYME KINETICS; ENZYME PURIFICATION; GENE EXPRESSION SYSTEM; GENE MUTATION; GENETIC COMPLEMENTATION; GENOTYPE PHENOTYPE CORRELATION; MUTANT; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SITE DIRECTED MUTAGENESIS; STEADY STATE; WILD TYPE;

GENE EXPRESSION; HETEROZYGOTE; HUMANS; MUTAGENESIS, SITE-DIRECTED; MUTANT CHIMERIC PROTEINS; MUTATION; PHENYLALANINE; PHENYLALANINE HYDROXYLASE; PROMOTER REGIONS, GENETIC; RECOMBINANT PROTEINS;

EID: 79952698283     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2011.02.001     Document Type: Article

References (60)

1. Flatmark T., Stevens R.C. Structural insight into the aromatic amino acid hydroxylases and their disease-related mutant forms. Chem. Rev. 1999, 99:2137-2160.
2. Stokka A.J., Flatmark T. Substrate-induced conformational transition in human phenylalanine hydroxylase as studied by surface plasmon resonance analyses: the effect of terminal deletions, substrate analogues and phosphorylation. Biochem. J. 2003, 369:509-518.
3. Fusetti F., Erlandsen H., Flatmark T., Stevens R.C. Structure of tetrameric human phenylalanine hydroxylase and its implications for phenylketonuria. J. Biol. Chem. 1998, 273:16962-16967.
4. Bjørgo E., de Carvalho R.M., Flatmark T. A comparison of kinetic and regulatory properties of the tetrameric and dimeric forms of wild-type and Thr427→Pro mutant human phenylalanine hydroxylase: contribution of the flexible hinge region Asp425-Gln429 to the tetramerization and cooperative substrate binding. Eur. J. Biochem. 2001, 268:997-1005.
5. Gersting S.W., Staudigl M., Truger M.S., Messing D.D., Danecka M.K., Sommerhoff C.P., Kemter K.F., Muntau A.C. Activation of phenylalanine hydroxylase induces positive cooperativity toward the natural cofactor. J. Biol. Chem. 2010, 285:30686-30697.
6. Scriver C.R. The PAH gene, phenylketonuria, and a paradigm shift. Hum. Mutat. 2007, 28:831-845.
7. Scriver C.R., Hurtubise M., Konecki D., Phommarinh M., Prevost L., Erlandsen H., Stevens R., Waters P.J., Ryan S., McDonald D., Sarkissian C. PAHdb 2003: what a locus-specific knowledgebase can do. Hum. Mutat. 2003, 21:333-344.
8. Surtees R., Blau N. The neurochemistry of phenylketonuria. Eur. J. Pediatr. 2000, 159(Suppl 2):S109-S113.
9. National Institutes of Health Consensus Development Panel National Institutes of Health Consensus Development Conference statement: phenylketonuria: screening and management, October 16-18, 2000. Pediatrics 2001, 108:972-982.
10. Levy H.L., Milanowski A., Chakrapani A., Cleary M., Lee P., Trefz F.K., Whitley C.B., Feillet F., Feigenbaum A.S., Bebchuk J.D., Christ-Schmidt H., Dorenbaum A. Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study. Lancet 2007, 370:504-510.
11. Michals-Matalon K. Sapropterin dihydrochloride, 6-R-L-erythro-5, 6, 7, 8-tetrahydrobiopterin, in the treatment of phenylketonuria. Expert Opin. Investig. Drugs 2008, 17:245-251.
12. Zurflüh M.R., Zschocke J., Lindner M., Feillet F., Chery C., Burlina A., Stevens R.C., Thöny B., Blau N. Molecular genetics of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. Hum. Mutat. 2008, 29:167-175.
13. Kaufman S., Max E.E., Kang E.S. Phenylalanine hydroxylase activity in liver biopsies from hyperphenylalaninemia heterozygotes: deviation from proportionality with gene dosage. Pediatr. Res. 1975, 9:632-634.
14. Leandro J., Nascimento C., de Almeida I.T., Leandro P. Co-expression of different subunits of human phenylalanine hydroxylase: evidence of negative interallelic complementation. Biochim. Biophys. Acta, Mol. Basis Dis. 2006, 1762:544-550.
15. Howell P.L., Turner M.A., Christodoulou J., Walker D.C., Craig H.J., Simard L.R., Ploder L., McInnes R.R. Intragenic complementation at the argininosuccinate lyase locus: reconstruction of the active site. J. Inherit. Metab. Dis. 1998, 21(Suppl 1):72-85.
16. McInnes R.R., Shih V., Chilton S. Interallelic complementation in an inborn error of metabolism: genetic heterogeneity in argininosuccinate lyase deficiency. Proc. Natl Acad. Sci. U. S. A. 1984, 81:4480-4484.
17. Yu B., Thompson G.D., Yip P., Howell P.L., Davidson A.R. Mechanisms for intragenic complementation at the human argininosuccinate lyase locus. Biochemistry 2001, 40:15581-15590.
18. Ohgari Y., Sawamoto M., Yamamoto M., Kohno H., Taketani S. Ferrochelatase consisting of wild-type and mutated subunits from patients with a dominant-inherited disease, erythropoietic protoporphyria, is an active but unstable dimer. Hum. Mol. Genet. 2005, 14:327-334.
19. Christacos N.C., Fridovich-Keil J.L. Impact of patient mutations on heterodimer formation and function in human galactose-1-P uridylyltransferase. Mol. Genet. Metab. 2002, 76:319-326.
20. Elsevier J.P., Fridovich-Keil J.L. The Q188R mutation in human galactose-1-phosphate uridylyltransferase acts as a partial dominant negative. J. Biol. Chem. 1996, 271:32002-32007.
21. Hammarström P., Wiseman R.L., Powers E.T., Kelly J.W. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science 2003, 299:713-716.
22. Keetch C.A., Bromley E.H., McCammon M.G., Wang N., Christodoulou J., Robinson C.V. L55P transthyretin accelerates subunit exchange and leads to rapid formation of hybrid tetramers. J. Biol. Chem. 2005, 280:41667-41674.
23. Dridi W., Fetni R., Lavoie J., Poupon M.F., Drouin R. The dominant-negative effect of p53 mutants and p21 induction in tetraploid G1 arrest depends on the type of p53 mutation and the nature of the stimulus. Cancer Genet. Cytogenet. 2003, 143:39-49.
24. Nicholls C.D., McLure K.G., Shields M.A., Lee P.W. Biogenesis of p53 involves cotranslational dimerization of monomers and posttranslational dimerization of dimers. Implications on the dominant negative effect. J. Biol. Chem. 2002, 277:12937-12945.
25. Scriver C.R., Waters P.J. Monogenic traits are not simple: lessons from phenylketonuria. Trends Genet. 1999, 15:267-272.
26. Guldberg P., Rey F., Zschocke J., Romano V., Francois B., Michiels L., Ullrich K., Hoffmann G.F., Burgard P., Schmidt H., Meli C., Riva E., Dianzani I., Ponzone A., Rey J., Güttler F. A European multicenter study of phenylalanine hydroxylase deficiency: classification of 105 mutations and a general system for genotype-based prediction of metabolic phenotype. Am. J. Hum. Genet. 1998, 63:71-79.
27. Kayaalp E., Treacy E., Waters P.J., Byck S., Nowacki P., Scriver C.R. Human phenylalanine hydroxylase mutations and hyperphenylalaninemia phenotypes: a metanalysis of genotype-phenotype correlations. Am. J. Hum. Genet. 1997, 61:1309-1317.
28. Rivera I., Cabral A., Almeida M., Leandro P., Carmona C., Eusébio F., Tasso T., Vilarinho L., Martins E., Lechner M.C., de Almeida I.T., Konecki D.S., Lichter-Konecki U. The correlation of genotype and phenotype in Portuguese hyperphenylalaninemic patients. Mol. Genet. Metab. 2000, 69:195-203.
29. Trefz F.K., Scheible D., Götz H., Frauendienst-Egger G. Significance of genotype in tetrahydrobiopterin-responsive phenylketonuria. J. Inherit. Metab. Dis. 2009, 32:22-26.
30. Leandro J., Simonsen N., Saraste J., Leandro P., Flatmark T. Phenylketonuria as a protein misfolding disease: the mutation pG46S in phenylalanine hydroxylase promotes self-association and fibril formation. Biochim. Biophys. Acta 2011, 1812:106-120.
31. Waters P.J., Scriver C.R., Parniak M.A. Homomeric and heteromeric interactions between wild-type and mutant phenylalanine hydroxylase subunits: evaluation of two-hybrid approaches for functional analysis of mutations causing hyperphenylalaninemia. Mol. Genet. Metab. 2001, 73:230-238.
32. Kapust R.B., Waugh D.S. Escherichia coli maltose-binding protein is uncommonly effective at promoting the solubility of polypeptides to which it is fused. Protein Sci. 1999, 8:1668-1674.
33. Martínez A., Knappskog P.M., Olafsdottir S., Døskeland A.P., Eiken H.G., Svebak R.M., Bozzini M., Apold J., Flatmark T. Expression of recombinant human phenylalanine hydroxylase as fusion protein in Escherichia coli circumvents proteolytic degradation by host cell proteases. Isolation and characterization of the wild-type enzyme. Biochem. J. 1995, 306:589-597.
34. Knappskog P.M., Flatmark T., Aarden J.M., Haavik J., Martínez A. Structure/function relationships in human phenylalanine hydroxylase. Effect of terminal deletions on the oligomerization, activation and cooperativity of substrate binding to the enzyme. Eur. J. Biochem. 1996, 242:813-821.
35. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
36. Martínez A., Olafsdottir S., Haavik J., Flatmark T. Inactivation of purified phenylalanine hydroxylase by dithiothreitol. Biochem. Biophys. Res. Commun. 1992, 182:92-98.
37. LiCata V.J., Allewell N.M. Is substrate inhibition a consequence of allostery in aspartate transcarbamylase?. Biophys. Chem. 1997, 64:225-234.
38. Solstad T., Flatmark T. Microheterogeneity of recombinant human phenylalanine hydroxylase as a result of nonenzymatic deamidations of labile amide containing amino acids. Effects on catalytic and stability properties. Eur. J. Biochem. 2000, 267:6302-6310.
39. Fox J.D., Kapust R.B., Waugh D.S. Single amino acid substitutions on the surface of Escherichia coli maltose-binding protein can have a profound impact on the solubility of fusion proteins. Protein Sci. 2001, 10:622-630.
40. Leandro P., Rivera I., Lechner M.C., de Almeida I.T., Konecki D. The V388M mutation results in a kinetic variant form of phenylalanine hydroxylase. Mol. Genet. Metab. 2000, 69:204-212.
41. Arnau J., Lauritzen C., Petersen G.E., Pedersen J. Current strategies for the use of affinity tags and tag removal for the purification of recombinant proteins. Protein Expr. Purif. 2006, 48:1-13.
42. Waugh D.S. Making the most of affinity tags. Trends Biotechnol. 2005, 23:316-320.
43. Dumon-Seignovert L., Cariot G., Vuillard L. The toxicity of recombinant proteins in Escherichia coli: a comparison of overexpression in BL21(DE3), C41(DE3), and C43(DE3). Protein Expr. Purif. 2004, 37:203-206.
44. Miroux B., Walker J.E. Over-production of proteins in Escherichia coli: mutant hosts that allow synthesis of some membrane proteins and globular proteins at high levels. J. Mol. Biol. 1996, 260:289-298.
45. Carvalho R.N., Solstad T., Bjørgo E., Barroso J.F., Flatmark T. Deamidations in recombinant human phenylalanine hydroxylase. Identification of labile asparagine residues and functional characterization of Asn→Asp mutant forms. J. Biol. Chem. 2003, 278:15142-15152.
46. Gräslund S., Nordlund P., Weigelt J., Hallberg B.M., Bray J., Gileadi O., Knapp S., Oppermann U., Arrowsmith C., Hui R., Ming J., dhe-Paganon S., Park H.W., Savchenko A., Yee A., Edwards A., Vincentelli R., Cambillau C., Kim R., Kim S.H., Rao Z., Shi Y., Terwilliger T.C., Kim C.Y., Hung L.W., Waldo G.S., Peleg Y., Albeck S., Unger T., Dym O., Prilusky J., Sussman J.L., Stevens R.C., Lesley S.A., Wilson I.A., Joachimiak A., Collart F., Dementieva I., Donnelly M.I., Eschenfeldt W.H., Kim Y., Stols L., Wu R., Zhou M., Burley S.K., Emtage J.S., Sauder J.M., Thompson D., Bain K., Luz J., Gheyi T., Zhang F., Atwell S., Almo S.C., Bonanno J.B., Fiser A., Swaminathan S., Studier F.W., Chance M.R., Sali A., Acton T.B., Xiao R., Zhao L., Ma L.C., Hunt J.F., Tong L., Cunningham K., Inouye M., Anderson S., Janjua H., Shastry R., Ho C.K., Wang D., Wang H., Jiang M., Montelione G.T., Stuart D.I., Owens R.J., Daenke S., Schütz A., Heinemann U., Yokoyama S., Büssow K., Gunsalus K.C. Protein production and purification. Nat. Methods 2008, 5:135-146.
47. Scheich C., Kümmel D., Soumailakakis D., Heinemann U., Büssow K. Vectors for co-expression of an unrestricted number of proteins. Nucleic Acids Res. 2007, 35:e43.
48. Tolia N.H., Joshua-Tor L. Strategies for protein coexpression in Escherichia coli. Nat. Methods 2006, 3:55-64.
49. Schmidt M., Romer L., Strehle M., Scheibel T. Conquering isoleucine auxotrophy of Escherichia coli BLR(DE3) to recombinantly produce spider silk proteins in minimal media. Biotechnol. Lett. 2007, 29:1741-1744.
50. Erlandsen H., Fusetti F., Martínez A., Hough E., Flatmark T., Stevens R.C. Crystal structure of the catalytic domain of human phenylalanine hydroxylase reveals the structural basis for phenylketonuria. Nat. Struct. Biol. 1997, 4:995-1000.
51. Kobe B., Jennings I.G., House C.M., Michell B.J., Goodwill K.E., Santarsiero B.D., Stevens R.C., Cotton R.G., Kemp B.E. Structural basis of autoregulation of phenylalanine hydroxylase. Nat. Struct. Biol. 1999, 6:442-448.
52. Gersting S.W., Kemter K.F., Staudigl M., Messing D.D., Danecka M.K., Lagler F.B., Sommerhoff C.P., Roscher A.A., Muntau A.C. Loss of function in phenylketonuria is caused by impaired molecular motions and conformational instability. Am. J. Hum. Genet. 2008, 83:5-17.
53. Andersen O.A., Stokka A.J., Flatmark T., Hough E. 2.0Å resolution crystal structures of the ternary complexes of human phenylalanine hydroxylase catalytic domain with tetrahydrobiopterin and 3-(2-thienyl)-l-alanine or l-norleucine: substrate specificity and molecular motions related to substrate binding. J. Mol. Biol. 2003, 333:747-757.
54. Li J., Dangott L.J., Fitzpatrick P.F. Regulation of phenylalanine hydroxylase: conformational changes upon phenylalanine binding detected by hydrogen/deuterium exchange and mass spectrometry. Biochemistry 2010, 49:3327-3335.
55. Stokka A.J., Carvalho R.N., Barroso J.F., Flatmark T. Probing the role of crystallographically defined/predicted hinge-bending regions in the substrate-induced global conformational transition and catalytic activation of human phenylalanine hydroxylase by single-site mutagenesis. J. Biol. Chem. 2004, 279:26571-26580.
56. Thórólfsson M., Teigen K., Martínez A. Activation of phenylalanine hydroxylase: effect of substitutions at Arg68 and Cys237. Biochemistry 2003, 42:3419-3428.
57. Aguado C., Pérez B., Ugarte M., Desviat L.R. Analysis of the effect of tetrahydrobiopterin on PAH gene expression in hepatoma cells. FEBS Lett. 2006, 580:1697-1701.
58. Erlandsen H., Pey A.L., Gámez A., Pérez B., Desviat L.R., Aguado C., Koch R., Surendran S., Tyring S., Matalon R., Scriver C.R., Ugarte M., Martínez A., Stevens R.C. Correction of kinetic and stability defects by tetrahydrobiopterin in phenylketonuria patients with certain phenylalanine hydroxylase mutations. Proc. Natl Acad. Sci. U. S. A. 2004, 101:16903-16908.
59. Pey A.L., Pérez B., Desviat L.R., Martínez M.A., Aguado C., Erlandsen H., Gámez A., Stevens R.C., Thórólfsson M., Ugarte M., Martínez A. Mechanisms underlying responsiveness to tetrahydrobiopterin in mild phenylketonuria mutations. Hum. Mutat. 2004, 24:388-399.
60. Eiken H.G., Knappskog P.M., Apold J., Flatmark T. PKU mutation G46S is associated with increased aggregation and degradation of the phenylalanine hydroxylase enzyme. Hum. Mutat. 1996, 7:228-238.